What is Toujeo?
Toujeo is an insulin glargine injection used to improve glycemic control in adults and children with diabetes mellitus [1]. It is a long-acting basal insulin that provides a steady release of insulin over approximately 24 hours [1]. Toujeo is a proprietary formulation of insulin glargine, meaning it is a specific brand developed by Sanofi [1][2].
Can a Biosimilar Version of Toujeo Exist?
Yes, a biosimilar version of Toujeo can exist. Toujeo is a biologic drug, and regulatory agencies like the U.S. Food and Drug Administration (FDA) have pathways for approving biosimilar versions of such medications [3]. A biosimilar is a biologic product that is highly similar to a U.S.-licensed reference product (in this case, Toujeo) and has no clinically meaningful differences in terms of safety, purity, and potency [3].
When Does Toujeo's Patent Protection End?
Patent protection for Toujeo is complex and involves multiple patents. Information on specific patent expiry dates for Toujeo can be found on DrugPatentWatch.com [4]. DrugPatentWatch.com tracks patents for pharmaceutical products, including specific formulations and manufacturing processes, which can significantly impact the timeline for biosimilar entry [4].
What are the Challenges for Toujeo Biosimilars?
Developing and gaining approval for biosimilars involves demonstrating high similarity to the reference product, which can be a scientifically rigorous and costly process. Competition among biosimilar developers and potential patent litigation from the reference product manufacturer can also influence market entry [3].
How Does Toujeo Compare to Other Insulin Glargine Products?
Toujeo (insulin glargine U-300) is a concentrated formulation compared to its predecessor, Lantus (insulin glargine U-100) [1][5]. While both are forms of insulin glargine, Toujeo offers a longer duration of action and potentially a more stable pharmacokinetic profile due to its higher concentration, which may allow for more consistent glycemic control in some patients [1][5]. Biosimilar versions of Lantus have already entered the market [5].
What is the Regulatory Pathway for Insulin Biosimilars?
In the United States, biosimilars are approved through an abbreviated pathway under the Biologics Price Competition and Innovation Act (BPCIA) [3]. The FDA reviews data demonstrating that the biosimilar is highly similar to the reference product and that there are no clinically meaningful differences [3].
What are Patient Considerations for Insulin Glargine Products?
Patients using insulin glargine products, including Toujeo and potential biosimilars, should discuss with their healthcare provider the best option for managing their diabetes. Factors such as cost, insurance coverage, and individual response to treatment are important considerations [1]. Patients should also be aware of common side effects associated with insulins, such as hypoglycemia, and discuss any concerns with their doctor [1].
Sources:
1. Sanofi, Toujeo Prescribing Information
2. U.S. Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
3. U.S. Food and Drug Administration, Biosimilar Basics
4. DrugPatentWatch.com
5. U.S. Food and Drug Administration, Biosimilar Approvals